Jundishapur Journal of Microbiology

Published by: Kowsar

Emergence of Staphylococcus epidermidis Clinical Isolates with Resistance to Both Mupirocin and Fusidic Acid

Chunchan Lin 1 , Shuying Chen 1 , Ye Jin 1 , Jingjing Duan 1 , Zhihao Hao 1 , Shanshan Wang 1 , Yinjuan Guo 1 , Longhua Hu 2 , Liangxing Wang 3 and Fangyou Yu 4 , *
Authors Information
1 Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2 Department of Clinical Microbiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
3 Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4 Department of Laboratory Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
Article information
  • Jundishapur Journal of Microbiology: September 2018, 11 (9); e62697
  • Published Online: August 18, 2018
  • Article Type: Research Article
  • Received: October 10, 2017
  • Revised: August 6, 2018
  • Accepted: August 7, 2018
  • DOI: 10.5812/jjm.62697

To Cite: Lin C, Chen S, Jin Y, Duan J, Hao Z, et al. Emergence of Staphylococcus epidermidis Clinical Isolates with Resistance to Both Mupirocin and Fusidic Acid, Jundishapur J Microbiol. 2018 ; 11(9):e62697. doi: 10.5812/jjm.62697.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27(4):870-926. doi: 10.1128/cmr.00109-13.
  • 2. Otto M. Molecular basis of Staphylococcus epidermidis infections. Sem Immunopathol. 2011;34(2):201-14. doi: 10.1007/s00281-011-0296-2.
  • 3. Otto M. Virulence factors of the coagulase-negative staphylococci. Front Biosci. 2004;9:841-63. [PubMed: 14766414].
  • 4. Onishi M, Urushibara N, Kawaguchiya M, Ghosh S, Shinagawa M, Watanabe N, et al. Prevalence and genetic diversity of arginine catabolic mobile element (ACME) in clinical isolates of coagulase-negative staphylococci: identification of ACME type I variants in Staphylococcus epidermidis. Infect Genet Evol. 2013;20:381-8. doi: 10.1016/j.meegid.2013.09.018. [PubMed: 24113082].
  • 5. Martins A, Cunha Mde L. Methicillin resistance in Staphylococcus aureus and coagulase-negative staphylococci: epidemiological and molecular aspects. Microbiol Immunol. 2007;51(9):787-95. [PubMed: 17895595].
  • 6. Nakama T, Nureki O, Yokoyama S. Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase. J Biol Chem. 2001;276(50):47387-93. doi: 10.1074/jbc.M109089200. [PubMed: 11584022].
  • 7. Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015;70(10):2681-92. doi: 10.1093/jac/dkv169. [PubMed: 26142407].
  • 8. Wang JL, Tang HJ, Hsieh PH, Chiu FY, Chen YH, Chang MC, et al. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2012;40(2):103-7. doi: 10.1016/j.ijantimicag.2012.03.010. [PubMed: 22612900].
  • 9. Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20(1):6-15. doi: 10.1684/ejd.2010.0833. [PubMed: 20007058].
  • 10. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 1999;12:S67-71. doi: 10.1016/s0924-8579(98)00075-2.
  • 11. Widerstrom M, Wistrom J, Sjostedt A, Monsen T. Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus. Eur J Clin Microbiol Infect Dis. 2012;31(1):7-20. doi: 10.1007/s10096-011-1270-6. [PubMed: 21533877].
  • 12. Miragaia M, Thomas JC, Couto I, Enright MC, de Lencastre H. Inferring a population structure for Staphylococcus epidermidis from multilocus sequence typing data. J Bacteriol. 2007;189(6):2540-52. doi: 10.1128/JB.01484-06. [PubMed: 17220222]. [PubMed Central: PMC1899367].
  • 13. Du X, Zhu Y, Song Y, Li T, Luo T, Sun G, et al. Molecular analysis of Staphylococcus epidermidis strains isolated from community and hospital environments in China. PLoS One. 2013;8(5). e62742. doi: 10.1371/journal.pone.0062742. [PubMed: 23675424]. [PubMed Central: PMC3652868].
  • 14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 26th informational supplement (M100-S26). Wayne, PA,USA: CLSI; 2016.
  • 15. Shahsavan S, Emaneini M, Noorazar Khoshgnab B, Khoramian B, Asadollahi P, Aligholi M, et al. A high prevalence of mupirocin and macrolide resistance determinant among Staphylococcus aureus strains isolated from burnt patients. Burns. 2012;38(3):378-82. doi: 10.1016/j.burns.2011.09.004. [PubMed: 22040930].
  • 16. Chen HJ, Hung WC, Tseng SP, Tsai JC, Hsueh PR, Teng LJ. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2010;54(12):4985-91. doi: 10.1128/AAC.00523-10. [PubMed: 20855746]. [PubMed Central: PMC2981276].
  • 17. Thomas JC, Vargas MR, Miragaia M, Peacock SJ, Archer GL, Enright MC. Improved multilocus sequence typing scheme for Staphylococcus epidermidis. J Clin Microbiol. 2007;45(2):616-9. doi: 10.1128/JCM.01934-06. [PubMed: 17151213]. [PubMed Central: PMC1829011].
  • 18. Lepainteur M, Royer G, Bourrel AS, Romain O, Duport C, Doucet-Populaire F, et al. Prevalence of resistance to antiseptics and mupirocin among invasive coagulase-negative staphylococci from very preterm neonates in NICU: the creeping threat? J Hosp Infect. 2013;83(4):333-6. doi: 10.1016/j.jhin.2012.11.025. [PubMed: 23414707].
  • 19. Hurdle JG, O'Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother. 2005;56(6):1166-8. doi: 10.1093/jac/dki387. [PubMed: 16275681]. [PubMed Central: PMC3319406].
  • 20. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, Paul-Ehrlich-Society for C. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int J Antimicrob Agents. 2004;23(6):577-81. doi: 10.1016/j.ijantimicag.2003.11.007. [PubMed: 15194128].
  • 21. Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, et al. Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother. 2013;57(1):559-68. doi: 10.1128/AAC.01633-12. [PubMed: 23147738]. [PubMed Central: PMC3535967].
  • 22. Park SY, Kim SM, Park SD. The prevalence, genotype and antimicrobial susceptibility of high- and low-level mupirocin resistant methicillin-resistant Staphylococcus aureus. Ann Dermatol. 2012;24(1):32-8. doi: 10.5021/ad.2012.24.1.32. [PubMed: 22363153]. [PubMed Central: PMC3283848].
  • 23. McLaws F, Chopra I, O'Neill AJ. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis. J Antimicrob Chemother. 2008;61(5):1040-3. doi: 10.1093/jac/dkn071. [PubMed: 18299637].
  • 24. Koksal F, Yasar H, Samasti M. Antibiotic resistance patterns of coagulase-negative staphylococcus strains isolated from blood cultures of septicemic patients in Turkey. Microbiol Res. 2009;164(4):404-10. doi: 10.1016/j.micres.2007.03.004. [PubMed: 17475456].
  • 25. Doudoulakakis A, Spiliopoulou I, Spyridis N, Giormezis N, Kopsidas J, Militsopoulou M, et al. Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections. J Clin Microbiol. 2017;55(8):2529-37. doi: 10.1128/JCM.00406-17. [PubMed: 28592549]. [PubMed Central: PMC5527431].
  • 26. Park SH, Kim JK, Park K. In vitro antimicrobial activities of fusidic acid and retapamulin against mupirocin- and methicillin-resistant Staphylococcus aureus. Ann Dermatol. 2015;27(5):551-6. doi: 10.5021/ad.2015.27.5.551. [PubMed: 26512169]. [PubMed Central: PMC4622889].
  • 27. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008;62(4):766-8. doi: 10.1093/jac/dkn266. [PubMed: 18567573].
  • 28. Udo EE, Jacob LE, Mathew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. J Med Microbiol. 2001;50(10):909-15. doi: 10.1099/0022-1317-50-10-909. [PubMed: 11599741].
  • 29. McLaws FB, Larsen AR, Skov RL, Chopra I, O'Neill AJ. Distribution of fusidic acid resistance determinants in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(3):1173-6. doi: 10.1128/AAC.00817-10. [PubMed: 21149625]. [PubMed Central: PMC3067117].
  • 30. Hung WC, Chen HJ, Lin YT, Tsai JC, Chen CW, Lu HH, et al. Skin commensal staphylococci may act as reservoir for fusidic acid resistance genes. PLoS One. 2015;10(11). e0143106. doi: 10.1371/journal.pone.0143106. [PubMed: 26581090]. [PubMed Central: PMC4651549].
  • 31. Mendes RE, Deshpande LM, Costello AJ, Farrell DJ. Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitals. Antimicrob Agents Chemother. 2012;56(9):4656-61. doi: 10.1128/AAC.00279-12. [PubMed: 22687512]. [PubMed Central: PMC3421855].
  • 32. Brenciani A, Morroni G, Pollini S, Tiberi E, Mingoia M, Varaldo PE, et al. Characterization of novel conjugative multiresistance plasmids carrying cfr from linezolid-resistant Staphylococcus epidermidis clinical isolates from Italy. J Antimicrob Chemother. 2016;71(2):307-13. doi: 10.1093/jac/dkv341. [PubMed: 26472766].
  • 33. Martinez-Melendez A, Morfin-Otero R, Villarreal-Trevino L, Camacho-Ortiz A, Gonzalez-Gonzalez G, Llaca-Diaz J, et al. Molecular epidemiology of coagulase-negative bloodstream isolates: detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23. Braz J Infect Dis. 2016;20(5):419-28. doi: 10.1016/j.bjid.2016.05.007. [PubMed: 27393769].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments